Chronic myelomonocytic leukemia (CMML) is a rare type of blood cancer. Some people live a long time with CMML, but others go on to develop acute myeloid leukemia (AML). Chronic myelomonocytic ...

Grenada's Chief Medical Officer Dr Shawn Charles has confirmed that Chikungunya and Zika, two vector borne viruses that are ...

We present a case of acute-onset orbital inflammation with rapidly progressive proptosis, episcleral venous stasis with raised intraocular pressure and loss of vision in a patient with a recent ...

Test Valley Golf Club, in Basingstoke, fundraised for Leukaemia Care after one of their members was diagnosed with a rare form of leukaemia.

Dr. Kolibaba is Instructor of Medicine, Division of Hematology and Medical Oncology, and Dr. Druker is Associate Professor of Medicine, Division of Hematology and Medical Oncology, Department of ...

*仅供医学专业人士阅读参考把肿瘤微环境内因抗原慢性刺激转入耗竭状态的CD8+T细胞“叫醒”，让它们重新活化为效应CD8+T细胞，是PD-1/L1抑制剂为代表的现有免疫治疗起效的关键，但实话实说，激活处在耗竭状态的CD8+T细胞，在奇点糕眼里总觉得有点 ...

Novel molecular risk factors in patients with chronic myelomonocytic leukemia (CMML) and myeloproliferative neoplasms. Novel treatment strategies for patients with MDS. Alpha 1 anti-trypsin for ...

Michael’s visionary philanthropy has also led to establishing a translational patient-centred research group to investigate an unusual type of chronic leukaemia (CMML). Michael is also playing a ...

消息面上，宜明昂科公告，董事会欣然宣布，IMM0306治疗系统性红斑狼疮 (SLE)的Ib期临床试验成功完成首例患者给药。由集团独立研发的IMM0306是一种靶向分化簇47 (CD47)及分化簇20 (CD20)的双特异性分子，是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。截至本公告日期，集团拥有IMM0306的全球知识产权及商业化权利。

慢性嗜酸性粒细胞白血病（Chroniceosinophilicleukemia，CEL）是一种罕见的骨髓增殖性肿瘤，以外周血和骨髓中嗜酸性粒细胞异常增多为特征，可浸润多 ...

2024年10月22日，港股市场迎来宜明昂科-B(01541)的显著异动，早盘股价一度上涨超过13%，截至发稿时，涨幅缩至4.63%，当前报价为5.65港元，日成交额达到6485.81万港元。这一波动主要源于公司旗下重要产品IMM01进入III期临床试验阶段，标志着该公司在抗癌领域的研发进展取得新突破。 IMM01作为宜明昂科的关键产品，正在针对多种癌症适应症进行临床研究，包括R/RcHL（复发/ ...